Central Precocious Puberty - Pipeline Insight - 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Central Precocious Puberty – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Precocious Puberty pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Central Precocious Puberty: Overview
Precocious puberty means an abnormally early onset of puberty. A sequence of events occurs during which a child develops into a young adult beginning at an unexpectedly early age. Glands that secrete growth and sex hormones begin to function abnormally early in life resulting in this condition Precocious puberty can occur in several forms. Central precocious puberty (CPP) can be caused by CNS tumors (craniopharyngioma, glioma, etc.) and other CNS disorders including: hypothalamic hamartoma of the tuber cinereum, encephalitis, brain abscess, static encephalopathy, global delays, sarcoid or tubercular granuloma, head trauma, vascular lesion, cranial irradiation, or neurofibromatosis type 1 (usually associated with optic glioma).
Symptoms
The symptoms of Central Precocious Puberty include:
The gold standard for determination of pubertal gonadotropin secretion is the GnRH stimulation test, though many clinicians start with a sensitive measurement of serum LH. Skeletal age determination is frequently obtained early in the work-up, and can be helpful in distinguishing isolated signs of puberty, which do not typically cause advancement in bone age as compared to true Precocious Puberty (PP), which will advance bone maturity. In boys, serum DHEAS, testosterone, 17-OH progesterone and ?-HCG levels are useful for the diagnosis of GIPP. In girls, serum DHEAS, estradiol and 17-OH progesterone levels are useful. Diagnostic studies including head MRI and pelvic ultrasound are frequently required in the work-up of children with Precocious Puberty.
Treatment
Treatment with very potent, long acting GnRH analogues have resulted in significant improvement in height in many, although not all, children with PP caused by both organic conditions and idiopathic CPP, with the best treatment outcomes seen in those with onset of puberty before 6 years of age GnRH superactive agonists work by first stimulating and then, after a few days, suppressing pulsatile LH and FSH release. This leads to suppression of gonadal steroid production. Management of GIPP requires removal of the hormone source (i.e. gonadal or adrenal tumor, exogenous hormone etc. The addition of androgen receptor blockers has been helpful in treating FMPP and MAS in boys. Pure estrogen receptor blocker, fulvestrant, is currently being investigated for the treatment of MAS in females with promising results.
Central Precocious Puberty Emerging Drugs Chapters
This segment of the Central Precocious Puberty report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Central Precocious Puberty Emerging Drugs
Further product details are provided in the report
Central Precocious Puberty: Therapeutic Assessment
This segment of the report provides insights about the different Central Precocious Puberty drugs segregated based on following parameters that define the scope of the report, such as:
Central Precocious Puberty: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Precocious Puberty therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Precocious Puberty drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Central Precocious Puberty – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Precocious Puberty pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Central Precocious Puberty: Overview
Precocious puberty means an abnormally early onset of puberty. A sequence of events occurs during which a child develops into a young adult beginning at an unexpectedly early age. Glands that secrete growth and sex hormones begin to function abnormally early in life resulting in this condition Precocious puberty can occur in several forms. Central precocious puberty (CPP) can be caused by CNS tumors (craniopharyngioma, glioma, etc.) and other CNS disorders including: hypothalamic hamartoma of the tuber cinereum, encephalitis, brain abscess, static encephalopathy, global delays, sarcoid or tubercular granuloma, head trauma, vascular lesion, cranial irradiation, or neurofibromatosis type 1 (usually associated with optic glioma).
Symptoms
The symptoms of Central Precocious Puberty include:
- Testicular enlargement (>3 ml) and/or pubic hair development in boys,
- Breast and/or pubic hair development in girls.
- Acne,
- Growth acceleration,
- Voice changes,
- Vaginal discharge or bleeding,
- Advanced skeletal maturation.
The gold standard for determination of pubertal gonadotropin secretion is the GnRH stimulation test, though many clinicians start with a sensitive measurement of serum LH. Skeletal age determination is frequently obtained early in the work-up, and can be helpful in distinguishing isolated signs of puberty, which do not typically cause advancement in bone age as compared to true Precocious Puberty (PP), which will advance bone maturity. In boys, serum DHEAS, testosterone, 17-OH progesterone and ?-HCG levels are useful for the diagnosis of GIPP. In girls, serum DHEAS, estradiol and 17-OH progesterone levels are useful. Diagnostic studies including head MRI and pelvic ultrasound are frequently required in the work-up of children with Precocious Puberty.
Treatment
Treatment with very potent, long acting GnRH analogues have resulted in significant improvement in height in many, although not all, children with PP caused by both organic conditions and idiopathic CPP, with the best treatment outcomes seen in those with onset of puberty before 6 years of age GnRH superactive agonists work by first stimulating and then, after a few days, suppressing pulsatile LH and FSH release. This leads to suppression of gonadal steroid production. Management of GIPP requires removal of the hormone source (i.e. gonadal or adrenal tumor, exogenous hormone etc. The addition of androgen receptor blockers has been helpful in treating FMPP and MAS in boys. Pure estrogen receptor blocker, fulvestrant, is currently being investigated for the treatment of MAS in females with promising results.
Central Precocious Puberty Emerging Drugs Chapters
This segment of the Central Precocious Puberty report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Central Precocious Puberty Emerging Drugs
- Fulvestrant: AstraZeneca
- Bicalutamide: AstraZeneca
Further product details are provided in the report
Central Precocious Puberty: Therapeutic Assessment
This segment of the report provides insights about the different Central Precocious Puberty drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Central Precocious Puberty
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Central Precocious Puberty: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Precocious Puberty therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Precocious Puberty drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Central Precocious Puberty R&D. The therapies under development are focused on novel approaches to treat/improve Central Precocious Puberty.
- Central Precocious Puberty Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Central Precocious Puberty drugs?
- How many Central Precocious Puberty drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Central Precocious Puberty?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Central Precocious Puberty therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Central Precocious Puberty and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- Fulvestrant
- Bicalutamide
Introduction
Executive Summary
Central Precocious Puberty: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Central Precocious Puberty – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Central Precocious Puberty s companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Central Precocious Puberty Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Fulvestrant: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Central Precocious Puberty Key Companies
Central Precocious Puberty Key Products
Central Precocious Puberty- Unmet Needs
Central Precocious Puberty- Market Drivers and Barriers
Central Precocious Puberty- Future Perspectives and Conclusion
Central Precocious Puberty Analyst Views
Central Precocious Puberty Key Companies
Appendix
Executive Summary
Central Precocious Puberty: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Central Precocious Puberty – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Central Precocious Puberty s companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Central Precocious Puberty Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Fulvestrant: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Central Precocious Puberty Key Companies
Central Precocious Puberty Key Products
Central Precocious Puberty- Unmet Needs
Central Precocious Puberty- Market Drivers and Barriers
Central Precocious Puberty- Future Perspectives and Conclusion
Central Precocious Puberty Analyst Views
Central Precocious Puberty Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Central Precocious Puberty
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Central Precocious Puberty
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Central Precocious Puberty
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Central Precocious Puberty
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
